<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422328</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055-314</org_study_id>
    <secondary_id>2017-003934-10</secondary_id>
    <nct_id>NCT03422328</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.</brief_title>
  <acronym>UMBRELLA</acronym>
  <official_title>mUlticenter, Single-arM, Open-laBel, Long-teRm Safety Study With macitEntan in Patients With puLmonary Arterial Hypertension previousLy Treated With mAcitentan in Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to study the long-term safety of macitentan and to provide continued&#xD;
      treatment with macitentan to patients with pulmonary arterial hypertension (PAH) and Chronic&#xD;
      thromboembolic pulmonary hypertension (CTEPH) who were previously treated with macitentan in&#xD;
      clinical studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to provide continued treatment with macitentan to subjects with&#xD;
      PAH or CTEPH who participated in &quot;parent studies&quot; and to continue to accrue long-term safety&#xD;
      data. The design of this study is widely used in clinical programs to give participants in a&#xD;
      clinical study access to an effective study treatment beyond completion of the parent study.&#xD;
      This is considered the best option to collect long-term safety and tolerability information&#xD;
      of macitentan 10 mg and survival status of participants with PAH and CTEPH. &quot;Parent&#xD;
      study/studies&quot; refer to a number of clinical studies with macitentan that are conducted in&#xD;
      different clinical classification of PAH and CTEPH (NCT00667823, NCT02112487, NCT02310672,&#xD;
      NCT02968901, NCT02558231, NCT02382016, NCT02060721) and may be completed before the&#xD;
      participants have access to commercial macitentan in their country of residence. The &quot;parent&#xD;
      studies&quot; are fully or partially running in countries where no access to commercial macitentan&#xD;
      is expected in the near future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Anticipated">December 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is designed as an open-label, single-arm, multicenter trial in which all participants roll over from a &quot;parent study&quot; in order to continue their dose of macitentan 10 mg once every day as already received in the &quot;parent study&quot;.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident Rate of Treatment-emergent Adverse Event</measure>
    <time_frame>From Day 1 to End of study (EoS) visit (an average of 3 years)</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A treatment-emergent AE is any AE temporally associated with the use of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident rate of treatment-emergent adverse events (AEs) leading to premature discontinuation of study treatment</measure>
    <time_frame>From Day 1 to EoS visit (an average of 3 years)</time_frame>
    <description>Any AE will be recorded that 1) is (temporally) associated with the use of study treatment whether or not considered by the investigator as related to study treatment and 2) leads to premature discontinuation of study medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident rate of treatment-emergent serious adverse events (SAEs)</measure>
    <time_frame>From Day 1 to EoS visit (an average of 3 years)</time_frame>
    <description>Any SAE as defined by the ICH guidelines will be recorded. Any hepatic AE that leads to discontinuation of study treatment will be defined as SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of pregnancies with maternal exposure to macitentan</measure>
    <time_frame>From Day 1 to EoS visit (an average of 3 years)</time_frame>
    <description>Pregnancies with maternal exposure to macitentan will be recorded.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change of WHO functional class to each scheduled time point</measure>
    <time_frame>From Day 1 to EoT visit (an average of 3 years)</time_frame>
    <description>The proportion of patients who worsened, remain unchanged or improved from baseline to each scheduled time-point in WHO function will be calculated, where baseline is the initial baseline from the &quot;parent study&quot; (or the double-blind core study preceding the &quot;parent study&quot;).</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of survival status at End-of-Study (EoS)</measure>
    <time_frame>From Day 1 to EoS visit (an average of 3 years)</time_frame>
    <description>Time to death of all causes up to EoS from the date of randomization or enrollment in the &quot;parent study&quot; (or the double-blind core study preceding the &quot;parent study&quot;) will be estimated.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Chronic Thromboembolic Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Open-label macitentan 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg macitentan film coated tablet, administered orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>macitentan</intervention_name>
    <description>macitentan 10 mg, film-coated tablet, oral use</description>
    <arm_group_label>Open-label macitentan 10 mg</arm_group_label>
    <other_name>ACT-064992</other_name>
    <other_name>JNJ-67896062</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent to take part in the study before any study mandated procedure.&#xD;
&#xD;
          2. Participants from one of the parent studies and: a) the sponsor has decided to&#xD;
             terminate the parent study in that country and b) the participant has completed the&#xD;
             end of treatment (EOT) Visit of the parent study&#xD;
&#xD;
          3. Women of childbearing potential are able to take part in the study if the following&#xD;
             applies: a) Urine pregnancy test is negative at Enrollment; b) Agreement to perform&#xD;
             monthly urine or serum pregnancy tests during the study and up to at least 30 days&#xD;
             after the study treatment discontinuation; and c) Agreement to adhere to the planned&#xD;
             contraception scheme from Enrollment up to at least 30 days after study treatment&#xD;
             discontinuation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hemoglobin less than 80 gram per liter (g/L)&#xD;
&#xD;
          2. Serum Aspartate aminotransferase (AST) and/or alanine aminotransferases (ALT) more&#xD;
             than three times the upper limit of normal range&#xD;
&#xD;
          3. Known and documented history of severe hepatic impairment that is Child-Pugh Class C.&#xD;
&#xD;
          4. Pregnant, planning to become pregnant, or breastfeeding&#xD;
&#xD;
          5. Known hypersensitivity to macitentan, its excipients, or drugs of the same class&#xD;
&#xD;
          6. Planned or current treatment with another investigational treatment up to 3 months&#xD;
             prior to Enrollment&#xD;
&#xD;
          7. Any known factor or disease that may interfere with treatment compliance, study&#xD;
             conduct, or interpretation of the results, such as drug or alcohol dependence or&#xD;
             psychiatric disease&#xD;
&#xD;
          8. Treatment with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole,&#xD;
             voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marek Sochor</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minsk Regional Clinical Hospital Of The Red Banner Of Labor</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Besançon -Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Bordeaux (Pessac)</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Cavale Blanche</name>
      <address>
        <city>Brest Cedex 2</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH est - Hôpital Cardiovasculaire et Pneumologie Louis Pradel</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Côte de Nacre</name>
      <address>
        <city>Caen Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bicêtre - Aphp Hôpitaux Universitaires Paris-Sud</name>
      <address>
        <city>Le Kremlin Bicetre cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cardiologique - Chru Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hopital Nord Laënnec</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire - de Nice - Hopital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen - Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne - Hôpital Nord</name>
      <address>
        <city>St Priest en Jarez Cedex</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey CHU de Toulouse</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hôpital de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Pathology Research Institute of Siberian Branch of RAMS</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal North-West Medical Research Centre</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Scientific Institution</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CE 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiosurgery'</name>
      <address>
        <city>Dnipro</city>
        <zip>49059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>France</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <link>
    <url>http://pam.sylogent.com/cr/AC-055-314</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>macitentan</keyword>
  <keyword>long-term safety</keyword>
  <keyword>open-label</keyword>
  <keyword>single-arm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

